Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Merck Canada Inc.

Shouwu Miao

Kathleen M Rupprecht

Jianming Bao

Robert K Baker

William H Parsons

Frank Kayser

Jeffrey John Hale

John E Stelmach

Subharekha Raghavan

Cameron James Smith

Yi-Heng Chen

Petr Vachal

Alan Whitehead

Joie Garfunkle

Hubert B Josien

Srikanth Venkatraman

Yong Zhang

Guoqing Li

Jianmin Fu

Yan Guo

Linda Brockunier

Francisco Velazquez

Unmesh G Shah

Rui Zhang

Raphaelle Berger

Gang Ji

Murali Rajagopalan

Falong Jiang

Hong-Dong Li

David A Claremon

Nigel J Liverton

Samuel Chackalamannil

Ravi P Nargund

Yongxin Han

Duane A Burnett

Scott D Edmondson

Emma R Parmee

Peter J Sinclair

Feroze Ujjainwalla

James B Doherty

Yan Xia

Christopher F Claiborne

Sherman Tim Waddell

Ping Liu

Jason M Cox

John S Debenham

Eric J Gilbert

Zhuyan Guo

Wayne J Thompson

Patrick A Pinto

Ying-Duo Gao

Santhosh Francis Neelamkavil

Harry R Chobanian

Linus S Lin

Linda L Chang

Yu Jiang

Mariappan Chelliah

Christopher W Plummer

Takao Suzuki

Xibin Liao

Quang T Truong

Jiang Chang

Maria L Garcia

Gregory J Kaczorowski

Martin C Clasby

Meng-Hsin Chen

Hong Li

Thomas A Bara

Andrew Kotliar

Ping Lan

Sathesh P Bhat

Austin Chen

Julianne A Hunt

Jian Guo

Swaminathan R Natarajan

Joung L Goulet

Hyunjin M Kim

Luping Liu

Zhongxiang Sun

Keith Rosauer

Olga Ornoski

Dipshikha Biswas

Jonathan A Groeper

Marc D Chioda

Charles Jayne

Christopher B Forbes

Karen M Marcantonio

Xiaoqing Han

Florida Kallashi

Joan M Pierce

David D Wisnoski

Xingfang Hong

Jennifer Chee

Vince J Colandrea

Joan M Pierce (nee Fletcher)

Joan M Fletcher

Rowena D Ruzck

William A Schmalhofer

Chou Juitsai Liu

Nengxue Wang

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Soluble guanylate cyclase stimulators

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroazaindoles

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroindalones

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. 

Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Heterocycle-substituted 3-alkyl azetidine derivatives

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. 

Substituted 3-alkyl and 3-alkenyl azetidine derivatives

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.

Carbocyclic potassium channel inhibitors

The present invention is directed to pyrrolidine compounds of the formula I:

3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity

Growing community of inventors

Edison, NJ, United States of America

Shouwu Miao